Join
Live feed
·
PRReleasevia Quantisnow
NeuroSense Therapeutics Ltd. logo

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

ByQuantisnow·Wall Street's wire, on your screen.
NRSN· NeuroSense Therapeutics Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NRSN (NeuroSense Therapeutics Ltd.) and more on Quantisnow.